ES2886495T3 - Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas - Google Patents

Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas Download PDF

Info

Publication number
ES2886495T3
ES2886495T3 ES17793075T ES17793075T ES2886495T3 ES 2886495 T3 ES2886495 T3 ES 2886495T3 ES 17793075 T ES17793075 T ES 17793075T ES 17793075 T ES17793075 T ES 17793075T ES 2886495 T3 ES2886495 T3 ES 2886495T3
Authority
ES
Spain
Prior art keywords
benzoimidazol
butyl
hydroxy
diethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17793075T
Other languages
English (en)
Spanish (es)
Inventor
David Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Application granted granted Critical
Publication of ES2886495T3 publication Critical patent/ES2886495T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17793075T 2016-05-02 2017-05-01 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas Active ES2886495T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
ES2886495T3 true ES2886495T3 (es) 2021-12-20

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17793075T Active ES2886495T3 (es) 2016-05-02 2017-05-01 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas

Country Status (20)

Country Link
US (2) US10626092B2 (enExample)
EP (2) EP3939966A1 (enExample)
JP (1) JP2019514905A (enExample)
KR (1) KR20190005904A (enExample)
CN (1) CN109414425A (enExample)
AR (1) AR108257A1 (enExample)
AU (1) AU2017261218A1 (enExample)
BR (1) BR112018072439A2 (enExample)
CA (1) CA3022011A1 (enExample)
CL (1) CL2018003109A1 (enExample)
CO (1) CO2018012941A2 (enExample)
EA (1) EA201892341A1 (enExample)
ES (1) ES2886495T3 (enExample)
IL (1) IL262578A (enExample)
MA (1) MA44880A (enExample)
MX (1) MX382095B (enExample)
PH (1) PH12018502296B1 (enExample)
SG (1) SG11201809471UA (enExample)
TW (1) TW201741286A (enExample)
WO (1) WO2017192451A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291071B (zh) * 2017-02-28 2022-04-26 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) * 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003066889A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
DK1937650T3 (da) * 2005-09-08 2011-10-03 S Bio Pte Ltd Heterocykliske forbindelser
ES2703592T3 (es) * 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
SMT202000168T1 (it) 2012-10-30 2020-05-08 Mei Pharma Inc Terapie di combinazione per il trattamento dei tumori chemioresistenti

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
CN109414425A (zh) 2019-03-01
CO2018012941A2 (es) 2018-12-28
AR108257A1 (es) 2018-08-01
US20200317621A1 (en) 2020-10-08
MA44880A (fr) 2021-03-17
TW201741286A (zh) 2017-12-01
CA3022011A1 (en) 2017-11-09
JP2019514905A (ja) 2019-06-06
US10626092B2 (en) 2020-04-21
EA201892341A1 (ru) 2019-05-31
SG11201809471UA (en) 2018-11-29
EP3452035B1 (en) 2021-07-07
EP3939966A1 (en) 2022-01-19
PH12018502296B1 (en) 2022-04-06
MX382095B (es) 2025-03-13
KR20190005904A (ko) 2019-01-16
BR112018072439A2 (pt) 2019-02-19
WO2017192451A1 (en) 2017-11-09
MX2018013349A (es) 2019-02-20
US20190152923A1 (en) 2019-05-23
IL262578A (en) 2018-12-31
EP3452035A1 (en) 2019-03-13
EP3452035A4 (en) 2019-09-25
AU2017261218A1 (en) 2018-11-29
CL2018003109A1 (es) 2019-04-26

Similar Documents

Publication Publication Date Title
ES3034158T3 (en) Novel salt of terphenyl compound
ES3011209T3 (en) Salts of an lsd1 inhibitor
BR112015022857B1 (pt) Sal de omecamtiv mecarbil e processo para preparar sal
BR112019012140A2 (pt) composto, composição farmacêutica, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso de um composto
US20200317621A1 (en) Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof
US20240228438A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
ES2671608T3 (es) Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
ES2908572T3 (es) Formas cristalinas
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
KR102783080B1 (ko) [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
ES2384517T3 (es) Procedimiento para la producción de una sal de un aducto de ácido de un compuesto alcalino poliacídico
RU2761825C1 (ru) Соединения дейтерированного дефактиниба и их применение
ES2949414T3 (es) Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
ES2861050T3 (es) Procedimiento de producción de derivado de tiazol
ES2568245T3 (es) Solvatos cristalinos de hidrocloruro de 6-(piperidin-4-iloxi)-2H-isoquinolin-1-ona
US12595246B2 (en) Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
KR102965826B1 (ko) 헤테로고리 화합물, 이의 제조 방법 및 이의 용도
EP3934702A1 (en) [ 18f]-labeled benzothiazole derivative as pet radiotracer
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
HK40108981A (zh) 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
BR112020010148B1 (pt) Cocristal de ácido benzoico e um composto de sulfonamida, composição farmacêutica que o compreende e uso do mesmo
BR122026000702A2 (pt) Formas cristalinas de um inibidor de btk, seu uso e seu processo de produção, composição e combinação farmacêuticas, e kit
BR122025019374A2 (pt) Forma cristalina de composto de sulfonamida, sal de ácido benzoico, seus usos, seu método de preparação, composição farmacêutica que os compreende, e cocristal dos mesmos
PT1534667E (pt) Agonistas muscarínicos